Revium Recovery Inc. (RVRC)
Oxford Ledge is still expanding full research coverage of RVRC. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Revium Rx develops lipid-based nanoparticle therapies for infectious diseases, solid tumors, and vaccines through its acquired subsidiary LipoVation.
Source: 10-K · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 8-K Departure/election of directors or officers 2026-06-22
- 8-K Departure/election of directors or officers 2026-06-01
- 10-Q Quarterly financial report (unaudited) 2026-05-14
- 8-K Departure/election of directors or officers; Financial statements and exhibits 2026-04-20
- 10-K Annual financial report with audited statements 2026-03-31
Source: SEC EDGAR.
Annual results
1 year of annual figures for RVRC, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | — | -$13.4M | -$0.22 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
- Open RVRC in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.